Pathology News and Research

RSS

Pathology is the study and diagnosis of disease through examination of organs, tissues, bodily fluids, and whole bodies (autopsies). The term also encompasses the related scientific study of disease processes, called General pathology. Medical pathology is divided in two main branches, Anatomical pathology and Clinical pathology. Veterinary pathology is concerned with animal disease whereas Phytopathology is the study of plant diseases.

IRSF awards $2M for research into a cure for Rett syndrome

The International Rett Syndrome Foundation (IRSF) announced today that it is awarding grants totaling $2 million to support 18 innovative research projects in 2009. Each project will explore bold new ideas that have the potential to drive the field forward and speed the translation of research into treatments and a cure for Rett syndrome.

3 Oct 2009

Research study reveals primary chemotherapy benefits

Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.

3 Oct 2009

Co-marketing partnership between Enzo Life Sciences and BioTek Instruments

Enzo Biochem, Inc. announced today a co-marketing partnership between its Enzo Life Sciences subsidiary, a world leader in non-radioactive probe technology, and BioTek Instruments, a privately held global leader in the development, manufacture and sale of microplate instrumentation for drug discovery and life science applications, involving powerful, integrated solutions for high throughput live cell analysis.

3 Oct 2009

TMS closes final tranche of Series E Preferred Financing to a total of $6 million

TechniScan Medical Systems (TMS) Inc., a Salt Lake City-based developer of ultrasound technology for breast imaging, announced the close of the final tranche of their Series E Preferred Financing of $1.1 million, bringing the total raised in the Series E financing to just over $6 million.

1 Oct 2009

Rush University receives grants to study how epigenomic changes define cognitive decline

The National Institutes of Health has awarded Rush University Medical Center approximately $5.5 million in grants to study how epigenetic changes - chemical modifications to genes that result from diet, aging, stress, or environmental exposures - define and contribute to memory formation and cognitive decline. Results from the studies could profoundly alter the way the medical community understands, diagnoses, and treats Alzheimer's disease, according to the researchers.

1 Oct 2009

Axiomed Spine Corporation receives Ferchill Partner Award for its medical innovation

At the 6th Annual Cleveland Clinic Innovator Awards dinner, AxioMed Spine Corporation (www.axiomed.com) was awarded the Ferchill Partner Award for the company’s medical innovation and economic impact on the community. The Cleveland Clinic and AxioMed Spine Corporation collaborated on the development of the Freedom® Lumbar Disc for the treatment of degenerative disc disease.

1 Oct 2009

New research on brain and fear may help PTSD victims

The brain is a complex system made of billions of neurons and thousands of connections that relate to every human feeling, including one of the strongest emotions, fear. Most neurological fear studies have been rooted in fear-conditioning experiments. Now, University of Missouri researchers have started using computational models of the brain, making it easier to study the brain's connections.

1 Oct 2009

Social environment plays vital role in breast cancer

Social environment can play an important role in the biology of disease, including breast cancer, and lead to significant differences in health outcome, according to results of a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

1 Oct 2009

Biology and geography scientists explain the spread of HIV-1 epidemic in Africa

Scientists studying biology and geography may seem worlds apart, but together they have answered a question that has defied explanation about the spread of the HIV-1 epidemic in Africa.

1 Oct 2009

NCI and NHGRI collaborate to characterize genetic and genomic changes that occur in cancers

The University of North Carolina at Chapel Hill is one of twelve centers announced today by President Obama as part of an unprecedented large-scale, collaborative effort by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) to systematically characterize the genomic changes that occur in cancer.

1 Oct 2009

Aphios awarded NIH grant to develop pathogen inactivation technology for blood products

Aphios Corporation today announced that it has been awarded a RC-1 Challenge grant (No. 1RC1HL102822-01) from the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Health’s (NIH) American Recovery and Reinvestment Act (ARRA) funds to develop a generally-applicable pathogen inactivation technology for blood products.

30 Sep 2009

Mater Health Services implements Cisco Medical-Grade Network to improve health care

Cisco announced today that Mater Health Services, Queensland's largest not-for-profit hospital group, is making significant strides in achieving its Smart Hospital strategy with a roll-out of an expanded suite of business applications on its Cisco® Medical-Grade Network across its seven ultra-modern hospitals.

30 Sep 2009

The still elusive malaria vaccine

A deadly disease, malaria afflicts 350-500 million people worldwide each year and kills more than a million people. Transmitted by Anopheles mosquitoes, the disease occurs in more than 100 countries and territories, with at least 40 percent of the world's population at risk.

30 Sep 2009

Memorial Sloan-Kettering Cancer Center awards $50,000 to three young investigators

Three young investigators who have taken significant steps toward advancing the understanding of cancer will be the recipients of this year's Paul Marks Prize for Cancer Research, a prize awarded biennially since 2001 to scientists under the age of forty-six by Memorial Sloan-Kettering Cancer Center.

30 Sep 2009

NINDS: $50 billion spent each year for low back pain

A study by researchers at The George Institute for International Health in Australia found that it is rare for patients presenting to PCPs with acute lower back pain to have previously undiagnosed serious diseases. The most common serious disease cause documented was vertebral fracture, with half of the cases identified at the time of initial consultation.

29 Sep 2009

CIHR and CMAJ honour eight Canadian Health Researchers

The Canadian Institutes of Health Research (CIHR) and the Canadian Medical Association Journal (CMAJ) today honoured eight outstanding Canadian individuals and teams with the first ever CIHR-CMAJ Top Canadian Achievements in Health Research Awards, which recognize and celebrate Canadian health research and innovation excellence.

29 Sep 2009

Winners of Paul Marks Prize 2009

29 Sep 2009

UCLA discovery raises hope for curing genetic disorders caused by nonsense mutations

UCLA scientists have identified two chemicals that convince cells to ignore premature signals to stop producing important proteins. Published in the Sept. 28 edition of the Journal of Experimental Medicine, the findings could lead to new medications for genetic diseases, such as cancer and muscular dystrophy, that are sparked by missing proteins.

29 Sep 2009

Misregulation of SPAK protein may contribute to B-cell lymphoma development

A group led by Dr. Michael Teitell at UCLA has demonstrated that misregulation of the protein SPAK may contribute to B-cell lymphoma development. Their report can be found in the October 2009 issue of the American Journal of Pathology.

28 Sep 2009

FDA grants accelerated approval for Allos Therapeutics’ FOLOTYN

Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that last night the U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYNTM (pralatrexate injection) for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

28 Sep 2009

Pathology News and Research

Further Reading

IRSF awards $2M for research into a cure for Rett syndrome

Research study reveals primary chemotherapy benefits

Co-marketing partnership between Enzo Life Sciences and BioTek Instruments

TMS closes final tranche of Series E Preferred Financing to a total of $6 million

Rush University receives grants to study how epigenomic changes define cognitive decline

Axiomed Spine Corporation receives Ferchill Partner Award for its medical innovation

New research on brain and fear may help PTSD victims

Social environment plays vital role in breast cancer

Biology and geography scientists explain the spread of HIV-1 epidemic in Africa

NCI and NHGRI collaborate to characterize genetic and genomic changes that occur in cancers

Aphios awarded NIH grant to develop pathogen inactivation technology for blood products

Mater Health Services implements Cisco Medical-Grade Network to improve health care

The still elusive malaria vaccine

Memorial Sloan-Kettering Cancer Center awards $50,000 to three young investigators

NINDS: $50 billion spent each year for low back pain

CIHR and CMAJ honour eight Canadian Health Researchers

Winners of Paul Marks Prize 2009

UCLA discovery raises hope for curing genetic disorders caused by nonsense mutations

Misregulation of SPAK protein may contribute to B-cell lymphoma development

FDA grants accelerated approval for Allos Therapeutics’ FOLOTYN

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News